Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
Recruiting · NCT06826872 · Interventional (participants receive a specific treatment) · Lead sponsor: Shin Poong Pharmaceutical Co. Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
\- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses. \- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria. \- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions. \- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration. Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.
Who can take part
Inclusion criteria
- Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
Exclusion criteria
- Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.
Where it is running
1 location listed.
- CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea - Seoul, South Korea